What the evidence actually supports
Evidence reviewed: 2026-11-16
Semaglutide & Tirzepatide
These medicines have substantial human evidence for defined metabolic indications. Approval belongs to a product, indication and country—not to every vial bearing the molecule's name. Appetite effects are not proof of nervous-system regulation or dorsal-vagal shutdown.
Protect nutrition, strength and hydration with an individual plan. An Anchor, supplement bundle or fixed fasting window is not a medical prerequisite. Obesity treatment may be long term; stopping commonly leads to regain, and a taper is not proven to prevent it. Do not change prescribed treatment based on wearable readiness alone.
Pills, new pens and the metabolic pipeline
Oral Wegovy (semaglutide 25 mg) was approved in the US in December 2025 and in the EU on 15 July 2026; in OASIS 4 (307 adults without diabetes) mean weight change at 64 weeks was −13.6% versus −2.2% with placebo. On 1 April 2026 FDA approved Foundayo (orforglipron), the first once-daily GLP-1 pill without food or water timing rules; worth knowing that orforglipron is a small molecule, not a peptide at all. Wegovy injection also holds a US accelerated MASH indication (August 2025) for noncirrhotic disease with F2–F3 fibrosis; that is not a liver-detox or longevity claim.
A pill changes the route, not the biology: appetite still drops, so protein, strength training and hydration still decide what the lost weight is made of. Approval belongs to a product, indication and country; EU authorisation of oral Wegovy does not confirm Portuguese supply or reimbursement, and Foundayo's approval verified here is US-only.
Semaglutide: the eye-safety update
On 6 June 2025, EMA concluded that NAION, an optic-nerve condition, is a very rare adverse effect of semaglutide. Observational estimates in adults with type 2 diabetes corresponded to about one additional case per 10,000 person-years; that estimate is not a risk calculation for every individual.
Sudden vision loss or rapidly worsening eyesight requires urgent medical assessment. This warning is specific to semaglutide, not established as an identical risk for all peptides or incretin medicines. The clinician handles treatment decisions.
Retatrutide: the most-searched peptide nobody can legally sell
Retatrutide, Lilly's weekly GIP, GLP-1 and glucagon triple agonist, topped 2026 peptide searches before any regulator had approved it. In the phase 3 TRIUMPH-1 trial (2,339 adults without diabetes), company topline results reported mean weight loss of 28.3% on 12 mg at 80 weeks versus 2.2% on placebo. TRIUMPH-4 (knee osteoarthritis) reported 28.7% at 68 weeks; TRIUMPH-2 (type 2 diabetes, published in The Lancet) reported 20.8% at 80 weeks. Lilly plans to file with FDA in the first quarter of 2027.
Retatrutide is not authorised in the US, UK or EU, so anything sold as 'reta' outside a trial is an unlicensed product of unknown content. In October 2026 the MHRA seized more than 12,000 fake retatrutide and tirzepatide pens in Birmingham. Trial results came with screening, supervised dose escalation and follow-up; a grey-market vial supplies none of those.
Amylin: the second appetite signal
Amylin is a satiety hormone released with insulin, and it is the next lane after GLP-1. CagriSema (cagrilintide plus semaglutide) reported −20.4% versus −3.0% at 68 weeks in REDEFINE 1 and was still awaiting a US decision at this review. Lilly's selective amylin agonist eloralintide produced 9.5–20.1% mean weight loss versus 0.4% with placebo at 48 weeks in a 263-person phase 2 trial (Billings et al., The Lancet, 2025), and has moved into phase 3.
No approval of CagriSema or eloralintide was verified on 16 November 2026. Vials sold online as cagrilintide or 'amylin' are not these trial products. A second appetite brake makes under-eating easier, which makes protein and strength work more important, not less.
Tesamorelin
Tesamorelin (Egrifta) has been FDA-approved since 2010 for one use: reducing excess abdominal fat in adults with HIV-associated lipodystrophy. Its popularity as a general 'visceral fat' peptide borrows that label. The current label states it is not indicated for weight-loss management and that long-term cardiovascular safety has not been established.
It raises IGF-1, can worsen glucose tolerance and is contraindicated with active malignancy or pituitary disruption. Outside its indication, the decision belongs to a prescriber who is monitoring those numbers.
MOTS-c
MOTS-c is a peptide encoded in mitochondrial DNA. Changhan Lee and colleagues in Pinchas Cohen's lab (Cell Metabolism, 2015) showed it acting on AMPK energy signalling and diet-induced obesity in mice. That is a strong mechanism with a thin human chapter: FDA's July 2026 briefing found human safety and effectiveness data insufficient, even though MOTS-c is in the October 2026 US compounding policy.
No validated human weight-loss or longevity regimen exists. Exercise is the best-studied way to recruit the same energy-sensing machinery, and it comes with a safety record.